The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with ...
GlobalData on MSN8d
MHRA approves trofolastat for prostate cancer diagnostic imagingTrofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion ...
The MHRA has introduced seven new CERSIs to modernise healthcare regulation and accelerate patient access to innovative ...
GlobalData on MSN10d
MHRA launches new monthly safety bulletinsThe MHRA’s overall communications strategy seeks to make information more timely and comprehensible to healthcare ...
4basebio PLC has been granted Good Manufacturing Practice (GMP) certification by the UK’s Medicines and Healthcare products ...
News Medical on MSN2d
4basebio receives MHRA GMP licence for manufacture and supply of synthetic DNAPLC (AIM: 4BB) (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has received ...
News Medical on MSN5d
World first as MHRA approves trofolastat for diagnostic imaging of prostate cancer in menThe Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new monthly safety bulletins, which aim to make medical device and medicine safety information clearer and more ...
Seven new CERSIs came together to showcase how partnerships will modernise regulation in AI, clinical trials, and advanced therapies, bringing ...
As with all products, the MHRA will keep its safety under close review. Prostate cancer is one of the most common cancers in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback